首页> 外文会议>Conference on Therapeutic Laser Applications and Laser-Tissue Interactions >Photodynamic therapy of non melanoma skin cancer murine model by topical application of a novel mTHPC liposomal formulation
【24h】

Photodynamic therapy of non melanoma skin cancer murine model by topical application of a novel mTHPC liposomal formulation

机译:新型MTHPC脂质体制剂局部应用非黑素瘤皮肤癌模型的光动力学治疗

获取原文

摘要

Photodynamic therapy (PDT) has been used in the treatment of various skin diseases including non melanoma skin carcinomas (NMSC). However, until now there are no publications concerning the efficacy of PDT after topical application of mTHPC. Although topical photosensitizer application presents many advantages over systemic drug administration, ALA-induced protoporphyrin IX is the only sensitizer topically used so far. In the present study photodynamic efficacy of the highly potent sensitizer meso-tetra(hydroxyphenyl)chlorin (mTHPC), supplied in a novel liposome formulation is investigated after topical application in hairless SKH-HR1 mice, bearing non melanoma skin carcinomas. The drug was applied topically for drug - light interval of 4 hours. The fluence rates were 100 and 50 mW/cm2 and two total energy doses, 10 J/cm2 and 100 J/cm2 were studied in groups of 5 animals. Three PDT sessions were performed in each animal, once every 7 days. The final evaluation of PDT effects was performed 14 days after the 3rd PDT treatment by measuring the geometrical characteristics of tumors. The groups treated with 100 mW/cm2 presented a higher complete tumor remission than the group of 50 mW/cm2 but an unusual high mortality. In the group of 50 mW/cm2 and 100 J/cm2, although the complete tumor remission percentage is poor, the tumor growth rate was decreased. No lesion, papilloma, or tumor was observed in the treated area even six months after tumor remission. Furthermore tumours up to 7 mm were achieved to be treated, indicating that this novel mTHPC formulation could be used for deeper and not only superficial carcinomas or lesions.
机译:光动力疗法(PDT)已被用于治疗各种皮肤病,包括非黑色素瘤皮肤癌(NMSC)。然而,直到现在,目前没有关于PDT在MTHPC局部施用后PDT的疗效的出版物。虽然局部光敏剂应用呈现出对系统药物管理的许多优点,但Ala诱导的原子卟啉IX是迄今为止局部使用的唯一敏感剂。在本研究中,在无毛SKH-HR1小鼠的局部应用后,研究了在一种新型脂质体制剂中供应的高效敏化剂Meso-Tetra(羟基苯)的光动力学效果,在无毛的SKH-HR1小鼠中进行局部应用,轴承非黑色素瘤皮肤癌。该药物局部用于药物 - 光间隔为4小时。用5只动物的组研究,流量率为100和50mW / cm2,10J / cm 2和100J / cm2。每只动物进行三次PDT会话,每7天一次进行一次。通过测量肿瘤的几何特征,在第3 PDT处理后14天进行PDT效应的最终评估。用100mW / cm 2治疗的基团呈现比50mW / cm 2的肿瘤缓解更高,但不寻常的高死亡率。在50mW / cm 2和100 j / cm2的组中,虽然完全肿瘤缓解率差,但肿瘤生长速率降低。在肿瘤缓解后在治疗区域观察到甚至六个月内没有病变,乳头瘤或肿瘤。此外,达到高达7mm的肿瘤待处理,表明这种新的MTHPC制剂可用于更深,不仅是浅表性癌或病变。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号